Scientists at Chugai discovered an erythromycin-derived motilin agonist called Mitemcinal (aka GM-611 or 3'-N-dimethyl-11-deoxy-3'-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin.) Mitemcinal was believed to have strong prokinetic properties, similar to its parent molecule, but lack antibiotic properties.
pharmaceutical industry | Pharmaceutical industry | Pharmaceutical drug | pharmaceutical drug | Royal Pharmaceutical Society of Great Britain | Royal Pharmaceutical Society | Pharmaceutical Product Development | Kyoto Pharmaceutical University | International Society for Pharmaceutical Engineering | University of Veterinary and Pharmaceutical Sciences, Brno | University of Copenhagen Faculty of Pharmaceutical Sciences | Pharmaceutical formulation | Hisamitsu Pharmaceutical | BioMarin Pharmaceutical | Association of the British Pharmaceutical Industry |